$930,000.00 in Sales Expected for Esperion Therapeutics Inc (NASDAQ:ESPR) This Quarter
Equities analysts expect Esperion Therapeutics Inc (NASDAQ:ESPR) to announce $930,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Esperion Therapeutics’ earnings, with the highest sales estimate coming in at $1.00 million and the lowest estimate coming in at $900,000.00. The firm is expected to issue its next quarterly earnings report on Thursday, November 7th.
On average, analysts expect that Esperion Therapeutics will report full-year sales of $147.95 million for the current fiscal year, with estimates ranging from $146.40 million to $149.00 million. For the next year, analysts anticipate that the firm will report sales of $171.26 million, with estimates ranging from $115.34 million to $207.50 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Esperion Therapeutics.
Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($2.01) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.86) by ($0.15). The firm had revenue of $0.98 million for the quarter, compared to the consensus estimate of $1.05 million. During the same period in the previous year, the business posted ($1.71) EPS. The firm’s revenue for the quarter was up 9720.0% compared to the same quarter last year.
Shares of ESPR traded down $0.18 during trading hours on Wednesday, hitting $36.56. 279,136 shares of the stock were exchanged, compared to its average volume of 435,372. Esperion Therapeutics has a fifty-two week low of $33.13 and a fifty-two week high of $60.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.65 and a quick ratio of 5.65. The business has a 50-day moving average of $37.78 and a 200-day moving average of $44.26. The firm has a market capitalization of $998.52 million, a P/E ratio of -4.85 and a beta of 1.71.
In related news, CEO Timothy M. Mayleben purchased 5,000 shares of Esperion Therapeutics stock in a transaction on Friday, June 28th. The stock was acquired at an average cost of $46.00 per share, for a total transaction of $230,000.00. Following the completion of the acquisition, the chief executive officer now owns 66,163 shares of the company’s stock, valued at approximately $3,043,498. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Target N. V. Biotech purchased 50,000 shares of Esperion Therapeutics stock in a transaction on Tuesday, July 23rd. The stock was bought at an average price of $42.65 per share, with a total value of $2,132,500.00. Following the completion of the acquisition, the insider now directly owns 3,572,964 shares of the company’s stock, valued at approximately $152,386,914.60. The disclosure for this purchase can be found here. Insiders acquired 147,500 shares of company stock valued at $5,521,825 over the last 90 days. Corporate insiders own 7.70% of the company’s stock.
A number of large investors have recently bought and sold shares of the business. Natixis grew its holdings in Esperion Therapeutics by 72.9% in the second quarter. Natixis now owns 21,563 shares of the biopharmaceutical company’s stock worth $1,003,000 after purchasing an additional 9,095 shares during the period. Royal Bank of Canada grew its holdings in Esperion Therapeutics by 38.1% in the second quarter. Royal Bank of Canada now owns 2,938 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 811 shares during the period. Verition Fund Management LLC acquired a new stake in Esperion Therapeutics in the second quarter worth $225,000. ClariVest Asset Management LLC acquired a new stake in Esperion Therapeutics in the second quarter worth $4,139,000. Finally, Bamco Inc. NY grew its holdings in Esperion Therapeutics by 2.7% in the second quarter. Bamco Inc. NY now owns 188,500 shares of the biopharmaceutical company’s stock worth $8,769,000 after purchasing an additional 5,000 shares during the period.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Further Reading: What is a recession?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.